Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610

/PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has...

Related Keywords

China ,Taizhou ,Jiangsu ,Hong Kong , ,Stock Exchange Of Hong Kong ,Jiangsu Recbio Technology Co Ltd ,Press Release ,Stock Exchange ,Hong Kong Limited ,Jiangsu Recbio Technology Co ,Td ,